IOVA logo

Iovance Biotherapeutics, Inc. Common Stock

IOVA

IOVA: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

more

Show IOVA Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of IOVA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by IOVA's directors and management

Government lobbying spending instances

  • $170,000 Mar 14, 2023 Issue: Medicare/Medicaid
  • $260,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $260,000 Oct 11, 2022 Issue: Medicare/Medicaid Health Issues
  • $260,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 20, 2022 Issue: Medicare/Medicaid
  • $50,000 Apr 19, 2022 Issue: Health Issues
  • $50,000 Jan 20, 2022 Issue: Health Issues
  • $50,000 Jan 19, 2022 Issue: Medicare/Medicaid
  • $50,000 Oct 20, 2021 Issue: Medicare/Medicaid
  • $50,000 Oct 20, 2021 Issue: Health Issues
  • $50,000 Jul 20, 2021 Issue: Medicare/Medicaid
  • $50,000 Jul 19, 2021 Issue: Health Issues
  • $40,000 Apr 20, 2021 Issue: Medicare/Medicaid
  • $40,000 Apr 19, 2021 Issue: Health Issues
  • $30,000 Jan 21, 2021 Issue: Medicare/Medicaid
  • $30,000 Jan 19, 2021 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Aug. 01, 2023
  • Patent Title: Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion Jun. 06, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 16, 2023
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Apr. 18, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 03, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 20, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 06, 2022
  • Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Sep. 06, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Aug. 02, 2022
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 12, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 28, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 21, 2022
  • Patent Title: Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof Jun. 14, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 31, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 24, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 26, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 19, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 19, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Apr. 05, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 05, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Mar. 08, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 22, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 08, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Jan. 11, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 21, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 21, 2021
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Nov. 23, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Nov. 09, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Nov. 09, 2021
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Oct. 12, 2021
  • Patent Title: Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof Oct. 12, 2021
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Sep. 21, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Aug. 10, 2021
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jul. 13, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 06, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 06, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 22, 2021
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 08, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 25, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 18, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 23, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 23, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 16, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 16, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of IOVA in WallStreetBets Daily Discussion

IOVA News

Recent insights relating to IOVA

CNBC Recommendations

Recent picks made for IOVA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in IOVA

Corporate Flights

Flights by private jets registered to IOVA